Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALENE: Basimglurant for Seizures in TSC
NCT05059327Phase 2Completed
- Sponsor
- Noema Pharma
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of basimglurant in tuberous sclerosis complex (TSC), sponsored by Noema Pharma. Started Mar 2022; status: completed.
02
Drugs
basimglurant
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT05059327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059327.